CTI BioPharma Corp. (GB:0RLB)

CTI BioPharma (0RLB) Income Statement


CTI BioPharma Income Statement

Last quarter (Q1 2023), CTI BioPharma's total revenue was $24.12M, an increase of 950.81% from the same quarter last year. In Q1, CTI BioPharma's net income was $53.27M. See CTI BioPharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 75.77M$ 53.95M$ 0.00$ 0.00$ 3.35M$ 26.29M
Cost of Revenue
$ -322.00K$ -3.51M---$ 879.00K
Gross Profit
$ 73.76M$ 50.43M---$ 25.41M
Operating Expense
$ 60.99M$ 130.23M$ 95.33M$ 47.77M$ 43.26M$ 58.53M
Operating Income
$ 12.77M$ -79.80M$ -95.33M$ -47.77M$ -39.92M$ -32.24M
Net Non Operating Interest Income Expense
$ -15.26M$ -13.14M$ -2.42M$ -828.00K$ -351.00K$ -515.00K
Other Income Expense
$ 207.00K$ 56.00K$ -161.00K$ -3.85M$ 245.00K$ 3.40M
Pretax Income
$ -2.54M$ -92.99M$ -97.91M$ -52.45M$ -40.02M$ -29.35M
Tax Provision
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -2.54M$ -92.99M$ -97.91M$ -52.45M$ -40.02M$ -29.40M
Basic EPS
$ -0.41$ -0.81$ -1.09$ -0.74$ -0.69$ -0.52
Diluted EPS
$ -0.41$ -0.81$ -1.09$ -0.74$ -0.69$ -0.52
Basic Average Shares
$ 354.79M$ 114.69M$ 90.12M$ 71.14M$ 57.97M$ 56.07M
Diluted Average Shares
$ 354.79M$ 114.69M$ 90.12M$ 71.14M$ 57.97M$ 56.07M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 60.67M$ 126.72M$ 95.33M$ 47.77M$ 43.26M$ 58.53M
Net Income From Continuing And Discontinued Operation
$ -69.24M$ -92.99M$ -97.91M$ -52.45M$ -40.02M$ -29.32M
Normalized Income
$ -38.43M-$ -97.91M$ -52.45M$ -40.27M$ -28.43M
Interest Expense
$ 7.97M-$ 2.45M$ 511.00K$ 1.52M$ 1.73M
$ 13.36M$ -79.85M$ -95.45M$ -51.94M$ -38.50M$ -27.62M
$ 15.52M$ -77.90M$ -94.93M$ -51.41M$ -37.95M$ -27.02M
Currency in USD

CTI BioPharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis